Because of the high malignancy of pancreatic ductal adenocarcinoma, the cancer-related mortality of pancreatic ductal adenocarcinoma is increasing year by year. Despite advance in surgical techniques, the 5-year survival rate of patients after resection is still less than 30%. Recent studies have found that pancreatic ductal adenocarcinoma is a systemic disease, which may not be cured completely by up-front resection, but requires perioperative multidisciplinary therapy. With the concept of "potentially curable pancreatic cancer" , clinicians need to evaluate the resectability of pancreatic ductal adenocarcinoma accurately before operation, and use the innovative multidisciplinary therapy including neoadjuvant chemoradiotherapy,surgery and adjuvant chemoradiotherapy to improve the R0 resection rate and reduce the risk of early metastasis. Therefore, the therapeutic goal of pancreatic ductal adenocarcinoma is no longer "simple resection" , but long survival through perioperative multidisciplinary treatment. In this article, we briefly introduce the progress of resectability assessment, surgical techniques and perioperative adjuvant therapy of "potentially curable pancreatic cancer" .
胰腺导管腺癌恶性程度极高，肿瘤相关死亡率逐年上升。尽管外科手术技术不断提高，但患者术后的5年生存率仍低于30%。近年来研究结果显示，胰腺导管腺癌是一种系统性疾病，一期切除难以彻底治愈，需要围手术期多学科治疗。随着"潜在可治愈胰腺癌"这一概念的提出，临床医师需要在术前对胰腺导管腺癌的可切除性进行准确评估，并通过新辅助放化疗、手术及辅助放化疗等多学科治疗，提高R0切除率并降低肿瘤早期转移风险。因此，对胰腺导管腺癌的治疗目标不再满足于"单纯的外科切除"，而是通过围手术期多学科治疗使患者获得长期生存。本文对"潜在可治愈胰腺癌"可切除性评估、手术技术、围手术期辅助治疗等研究进展进行简要介绍。.
Keywords: Chemotherapy, adjuvant; Operation; Pancreatic neoplasms; Radiotherapy, adjuvant.